Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.49 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020592 | 0.92 | P2RX3 (0.51) | GSTP1GSTM2HPGDP2RX3ALDH1A1 | |
| SCHEMBL23500769 | 0.90 | MEN1 (0.54) | GSTP1GSTM2HPGDP2RX3KMT2A | |
| SCHEMBL29837066 | 0.89 | MEN1 (0.45) | GSTP1GSTM2HPGDP2RX3ALDH1A1 | |
| SCHEMBL23500622 | 0.89 | MEN1 (0.45) | GSTP1GSTM2HPGDP2RX3ALDH1A1 | |
| SCHEMBL21471527 | 0.87 | GSTP1 (0.51) | GSTP1GSTM2HPGDP2RX3ALDH1A1 | |
| SCHEMBL28409562 | 0.87 | GSTP1 (0.51) | GSTP1GSTM2HPGDP2RX3ALDH1A1 | |
| SCHEMBL5020595 | 0.86 | HDAC1 (0.48) | GSTP1GSTM2P2RX3KMT2AMEN1 | |
| SCHEMBL25197301 | 0.86 | P2RX3 (0.49) | GSTP1GSTM2HPGDP2RX3ALDH1A1 | |
| SCHEMBL5020588 | 0.86 | P2RX3 (0.49) | GSTP1GSTM2HPGDP2RX3ALDH1A1 | |
| SCHEMBL5020590 | 0.86 | P2RX3 (0.45) | GSTP1GSTM2HPGDP2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020242245-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | 에스티팜 주식회사 | 2020-12-03 | — | — | WO | claimed |
| US-20250320203-A1 | 4-(3H-PYRAZOLO[4,3-F]QUINOLIN-7-YL)-N-(2-(DIMETHYLAMINO)ETHYL)BENZAMIDE- OR HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2025-10-16 | — | — | US | disclosed |
| CN-119278034-A | Selective histone deacetylase 8 (HDAC 8) degradants and methods of use thereof | 丹娜-法伯癌症研究院 | 2025-01-07 | — | — | CN | disclosed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-114685496-B | Hydroxamic acid based HDAC6 inhibitor synthesis and uses thereof | 广东晨康生物科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117384124-A | HDAC inhibitors, compositions and uses thereof | 安徽中医药大学 | 2024-01-12 | — | — | CN | disclosed |
| CN-116947763-A | 2-mercapto-5-cyano-6-aryl pyrimidine heterocyclic compound, preparation method and application | 郑州大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-112920167-B | Double-target inhibitor targeting FGFR and HDAC, preparation method and application thereof, pharmaceutical composition and medicament | 四川大学华西医院 | 2022-08-26 | — | — | CN | disclosed |
| US-20220235011-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| CN-114685496-A | Synthesis and application of hydroxamic acid based HDAC6 inhibitor | 佛山市晨康生物科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-109476605-B | benzo-N-hydroxyamide compounds with antitumor activity | 意大发马克股份公司 | 2022-05-31 | — | — | CN | disclosed |
| WO-2022037365-A1 | DOUBLE-TARGET INHIBITOR TARGETING FGFR AND HDAC, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITION AND MEDICAMENT | 四川大学华西医院 | 2022-02-24 | — | — | WO | disclosed |
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2060565-A1 | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases | 4SC AG (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-7169816-B2 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-03-09 | — | — | US | disclosed |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2005-03-03 | — | — | US | disclosed |
| US-6821963-B2 | PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES INHIBIT CERTAIN DUAL SPECIFICITY KINASE ENZYMES INVOLVED IN PROLIFERATIVE DISEASES SUCH AS CANCER, PSORIASIS AND RESTENOSIS; INHIBIT THE PHOSPHORYLATION OF MAP KINASE BY MEK | WARNER-LAMBERT COMPANY | 2004-11-23 | — | — | US | disclosed |
| US-4757078-A | Antiinflammatory agents, psoriasis | E. R. SQUIBB & SONS, INC. (US) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | GSTP1 4046/4885GSTM2 4285/4885HPGD 373/4885 |
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | HDAC1, HDAC11, MAP2K2 | GSTP1 3036/4885GSTM2 2761/4885HPGD 2275/4885 |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | GSTP1 4046/4885GSTM2 4285/4885HPGD 373/4885 |
| US-20220235011-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | SIRT6, SIRT1, SIRT2 | GSTP1 3013/4885GSTM2 3296/4885HPGD 741/4885 |
| US-20250320203-A1 | 4-(3H-PYRAZOLO[4,3-F]QUINOLIN-7-YL)-N-(2-(DIMETHYLAMINO)ETHYL)BENZAMIDE- OR HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PHKG1, PHKG2, MAP4K2 | GSTP1 3852/4885GSTM2 1994/4885HPGD 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.